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Objective: The liver performs a central role in regulating energy homeostasis by increasing glucose output during fasting. Recent studies on
Argonaute2 (Ago2), a key RNA-binding protein mediating the microRNA pathway, have illustrated its role in adaptive mechanisms according to
changes in metabolic demand. Here we sought to characterize the functional role of Ago2 in the liver in the maintenance of systemic glucose
homeostasis.
Methods: We first analyzed Ago2 expression in mouse primary hepatocyte cultures after modulating extracellular glucose concentrations and in
the presence of activators or inhibitors of glucokinase activity. We then characterized a conditional loss-of-function mouse model of Ago2 in liver
for alterations in systemic energy metabolism.
Results: Here we show that Ago2 expression in liver is directly correlated to extracellular glucose concentrations and that modulating gluco-
kinase activity is adequate to affect hepatic Ago2 levels. Conditional deletion of Ago2 in liver resulted in decreased fasting glucose levels in
addition to reducing hepatic glucose production. Moreover, loss of Ago2 promoted hepatic expression of AMP-activated protein kinase a1
(AMPKa1) by de-repressing its targeting by miR-148a, an abundant microRNA in the liver. Deletion of Ago2 from hyperglycemic, obese, and
insulin-resistant Lepob/ob mice reduced both random and fasted blood glucose levels and body weight and improved insulin sensitivity.
Conclusions: These data illustrate a central role for Ago2 in the adaptive response of the liver to fasting. Ago2 mediates the suppression of
AMPKa1 by miR-148a, thereby identifying a regulatory link between non-coding RNAs and a key stress regulator in the hepatocyte.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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During fasting, the liver engages several mechanisms to facilitate
hepatic glucose production. Central to this process are glycogenolysis
and gluconeogenesis, which are strictly regulated at the transcriptional
level to ensure expression of the enzymes catalyzing the rate limiting
steps of these pathways [1]. These processes are also known to be
impacted by post-translational modifications, as well as neuronal,
nutrient, and hormonal signaling mechanisms [2,3]. Recent studies
have now identified post-transcriptional regulators of liver function
including non-coding RNAs and inhibition of abundant microRNAs in
the liver including miR-122, miR-103/107, and miR-148a has been
shown to affect energy metabolism, tumorigenesis, and insulin
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www.molecularmetabolism.comInterestingly, liver-specific deletion of miR-122 in mice reveals a
complex phenotype including hepatosteatosis, increased inflamma-
tion, and spontaneous tumor formation [5,7]. This indicates that miR-
122 is unique in that other miRNAs co-expressed in the liver cannot
functionally compensate for its absence. Previous studies have re-
ported that miR-122 is the most abundant sequence in the total miRNA
pool, and the pronounced phenotype of the knockout mouse may also
reflect this dominance over the expression profile [8]. This may also
explain how albumin-Cre-mediated deletion of Dicer in mice recapit-
ulated many of the phenotypic traits of the miR-122-knockout mice
including the hepatosteatosis and hepatocarcinogenesis [9,10]. These
results emphasizing altered lipid metabolism and tumorigenesis after
abolishing miR-122 and Dicer expression provide strong evidence for
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Original Articleenergy metabolism in the liver; however the full extent of its contri-
bution remains to be elucidated.
The Argonaute family of proteins (Ago1-4) are essential regulators of
microRNA function by mediating their interaction with target mRNAs
and we recently showed loss of Argonaute2 (Ago2), the highest
expressed member of this family, in the pancreatic b-cell abolished
compensatory proliferation during insulin resistance indicating that it
serves in an adaptive capacity; however, it is unclear whether this
function extends to other tissues essential to energy metabolism
[11,12]. We also observed Ago2 expression in the b-cell was modu-
lated in accordance to glucose metabolism providing further evidence
that its function is directly linked to cellular energy homeostasis [13].
Moreover, the alterations in Ago2 expression in the b-cell were tran-
sient suggesting this form of post-transcriptional regulation may
cooperate with other cellular mechanisms in managing the energy
demands of the cell. In this study, we show Ago2 expression in the liver
is modulated according to changes in extracellular glucose concen-
trations and conditional deletion in the hepatocyte diminished adaptive
glucose production during fasting. Loss of Ago2 led to a concomitant
increase in AMPKa expression indicating gene regulation by non-
coding RNAs also overlaps with prominent signaling pathways man-
aging cellular stress in the hepatocyte. Together these results identify
Ago2 as an essential regulator of the fasting response of the liver and
further reinforce the role of this RNA-binding protein and microRNAs in
adaptive physiologic processes.
2. MATERIALS AND METHODS
2.1. Animals
Mice were maintained on a 12-hour light/dark cycle with ad libitum
access to regular chow food, or ketogenic diet (cat. No. E15149-30,
ssniff Spezialdiäten GmbH) in accordance with requirements estab-
lished by Landesamt für Gesundheit und Soziales (LAGeSo). All
experimental procedures were approved under protocols G 0357/10, G
0204/14, O 0405/09, and T 0436/08. Albumin-Cre-expressing mice
on the C57BL/6 background were directly crossed to Ago2-floxed mice
that were also on the C57BL/6 background (Alb-Cre, Ago2flox/flox). The
Ago2 heterozygous mice carrying the albumin-Cre allele were then
crossed to animals carrying the Lepob/ob allele (ob/Ago2Alb) (Jackson
Labs). Results were consistent in both genders; however, data from
female mice are not shown.
2.2. Analytic procedures
2.2.1. Quantification of metabolic parameters
Blood glucose levels were obtained with a One Touch glucometer
(Bayer) and plasma insulin measurements were measured by ELISA
(Crystal Chem, USA). Liver glycogen content was measured using the
Glycogen Colorimetric Assay Kit (Biovision).
2.2.2. Antibodies for western blot analysis
The following primary antibodies were used for western blotting at
1:1000 dilution: Ago2 (MBL CM004-3), Ago1 (MBL RN028PW),
Glucokinase (Abcam ab88056), b-Actin (Sigma A1978), GAPDH
(Abcam ab8245), a-Tubulin (Sigma, T6557), Glucose-6-phosphatase
(Abcam ab83690), Glycogen synthase (Cell Signaling, #3893), Insu-
lin receptor (Cell Signaling, #3025), Akt2 (Cell Signaling, #2964),
phospho-Akt2 (Ser474) (Cell Signaling, #8599), FoxO1 (Cell Signaling,
#2880), phospho-FoxO1 (Cell Signaling, #9464), Acetyl-CoA Carbox-
ylase (Cell Signaling, #3676), phospho-Acetyl-CoA Carboxylase (Cell
Signaling, #11818), Fatty Acid Synthase (Cell Signaling, #3180),16 MOLECULAR METABOLISM 18 (2018) 15e24  2018 The Authors. Published by Elsevier GmbH. TAMPKa (Cell Signaling, #2532), and phospho-AMPKa (Cell Signaling,
#2535). Image densitometry of 16-bit TIF images for all western blots
was performed using ImageJ.
2.2.3. Primary cell cultures
Primary hepatocytes were derived from livers of mice at age 10e12
weeks old and digested by collagenase, as previously described [14].
After centrifugation, tissue pellet was resuspended in DMEM (PAN
Biotech) containing 4.5 g/L glucose supplemented with 10% FBS and
50 mg/mL penicillin and 100 mg/mL streptomycin for plating. Hepa-
tocytes were cultured in 6-well plates coated with rat tail collagen I
(Corning #453236). Media was changed 16 h later to starvation media
containing 2.5 mM glucose supplemented with 0.5% v/v FBS and
50 mg/mL penicillin and 100 mg/ml streptomycin, until additional
treatments were performed. 2-deoxyglucose (Sigma #D8375) and RO-
28-1675 (ApexBio B1108) were solubilized in DMSO and added to the
starvation media at the specified concentrations and cells were treated
for 16 h before harvesting.
2.2.4. Isolation of mRNAs and miRNAs from ribonucleoprotein
immunoprecipitation (RIP)
RIP experiments were performed as described previously [15,16]. In
brief, the liver tissue from 16-hr fasted and random-fed C57BL/6 mice
was lysed using an equal volume of lysis buffer (20 mM Hepes,
150 mM NaCl, 1 mM CaCl2, 1 mM Mg Cl2). After 5 min incubation on
ice, lysates were frozen at 80 C to enhance lysis. Samples were
thawed on ice and spun for 15 min at 13,000 g and 4 C to remove cell
debris. Ago2 antibody (Wako cat. no. 018e22021) was incubated with
Dynabeads Protein G (Invitrogen, 10004D) was on a rotating wheel for
4 h at 4 C and beads were washed 5 times with wash buffer. Mouse
IgG1 antibody was used as a negative control. Cleared lysates were
incubated with beads overnight at 4 C. Afterwards, beads were
washed 5 times with elution buffer. RNA was extracted using the TRIzol
reagent (Life Technologies). Incorporated mRNA or miRNA was
quantified using qPCR and normalized by RNA from 10% input lysate.
2.2.5. Gene expression analysis
Total RNA was extracted using the TRIzol reagent (Invitrogen) and
cDNA was synthesized using RevertAid First Strand cDNA synthesis kit
(Fermentas). Quantitative real time PCR (qPCR) for microRNAs was
performed using ABI microRNA assays and normalized to U6 expres-
sion (Applied Biosystems). Expression of mRNAs was assessed using
gene-specific primers with FastStart SYBR Green PCR Master Mix
(Roche) on a StepOne Real-Time PCR System (ThermoFisher). All
primer sequences are available upon request. Luciferase assays were
performed after cloning the mouse AMPK 3‘UTR target site with the
primers, 50-TGGTAGCATAGCATAATGGG-30 and 50-CAACAGTTTATA-
GAGATATTCCTCAG-30 into a pGL3 reporter vector (Pp-luc) (Promega).
Co-transfection with miRNA mimics (Thermo Fisher Scientific) and a
pRL-TK control vector (Rr-luc) was performed on HEK293 cells, har-
vested after 48 h, and assayed according to manufacturer’s in-
structions (Promega). The control mimic pool was comprised of
equimolar amounts of 8 independent miRNA mimics and the final
transfected concentration was 200 nM.
2.2.6. Small RNA sequencing
Small RNA sequencing libraries were prepared using Illumina small
RNA library preparation kits as described [16]. Small RNA fraction with
a size range of 10e40 nucleotide (nt) were separated using flashPAGE
Fractionator (Ambion) according to the manufacturer’s instructions.
The small RNA fractions were ligated sequentially at the 30 and 50 endhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with synthetic RNA adapters, reverse transcribed and amplified using
Illumina sequencing primers. Amplified libraries were purified by
polyacrylamide gel electrophoresis (PAGE) according to the expected
product size and libraries were sequenced for 50 cycles (Illumina Hi-
seq 2000). The 30 adapter sequences were removed using a custom
Perl script and reads of length between 17 and 30 nt were mapped to
known mouse pre-miRNA sequences deposited in miRBase (http://
www.mirbase.org/) [17] without allowing any mismatch using soap1
and soap short [18], respectively.
2.3. Mouse phenotyping
Phenotyping analysis was performed in a ‘blinded’ manner; genotypes
were unknown to the investigator during the experimentation and age
of animals is stated in figure legends. All genotypes were present
during all experiments and randomization was implemented to the
extent that all animals were identified by number prior to analysis.
2.3.1. Tolerance tests
Glucose and pyruvate tolerance tests were performed following an
overnight fast (16 h) and injected intraperitoneally with either glucose
(2 g/kg body weight) or pyruvate (2 g/kg body weight in saline) as
described [19]. Insulin tolerance tests were performed after same day
fast (6 h) by injecting insulin (Sigma) intraperitoneally (0.75 U/kg body
weight).
2.4. Blood analyses
Clinical chemistry parameters in mouse plasma were measured on an
automated laboratory analyzer (Roche Cobas 8000). Plasma lipopro-
teins were isolated by sequential ultracentrifugation at density
<1.006 g/mL (very-low-density lipoprotein [VLDL]), 1.006  d 
1.063 g/mL (intermediate density lipoprotein, low-density lipoprotein
[LDL]), and d >1.063 g/mL (high-density lipoprotein [HDL]) as
described [20].
2.5. Statistical analysis
All results are expressed as mean  standard error (SEM), and sta-
tistical analysis is summarized in Supplementary Table 3. Comparisons
between data sets with two groups were evaluated using an unpaired
Student’s t-test. One-way and two-way repeated-measures ANOVA
analysis has been performed using GraphPad Prism Software Version
7 for comparisons of three or more groups. Post hoc statistics were
performed using Sidak’s multiple comparison test. A P-value of less
than or equal to 0.05 was considered statistically significant. The
presented data met the assumptions of the statistical tests used.
Normality and equal variances were tested using GraphPad Prism
software. No statistical methods were used to pre-determine sample
sizes, but our sample sizes are similar to those reported in previous
publications [19].
3. RESULTS
3.1. Argonaute2 expression in liver is modulated according to
glucose metabolism
Previous studies using the murine insulinoma-derived cell line MIN6
showed Ago2 expression to be regulated according to glucose meta-
bolism [13]. We observed that expression of Ago2 in this pancreatic b-
cell model increased in the presence of high glucose and hypothesized
that its role in miRNA-mediated gene regulation was pertinent for the
cellular adaptive response to increased glucose metabolism. Here we
sought to test whether Ago2 functions in a similar capacity by also
responding to changes in glucose metabolism in the liver. WeMOLECULAR METABOLISM 18 (2018) 15e24  2018 The Authors. Published by Elsevier GmbH. This is an open ac
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extracellular glucose and observed increased Ago2 and glucokinase
(Gck) expression at 15 and 25 mM glucose levels in comparison to
basal expression at 2.5 mM (Figure 1A). The increased expression of
these genes was in direct contrast to the reduction in genes mediating
gluconeogenesis including glucose-6-phosphatase (G6pc), pyruvate
carboxylase (Pc1), and phosphoenolpyruvate carboxykinase (Pepck)
(Figure 1B). We then tested whether pharmacological activation or
inhibition of glucose metabolism impacts hepatic Ago2 levels by
incubating primary mouse hepatocytes in the presence of 2-
deoxyglucose (2-DG) or the glucokinase activator RO-28-1675. Inhi-
bition of glucose metabolism with 2-DG abolished the increase in Ago2
expression in the presence of 25 mM glucose (Figure 1C,D) while
treatment with RO-28-1675 resulted in increased levels of Ago2
(Figure 1E). To further test the correlation between Ago2 levels and
cellular glucose metabolism in vivo, we next sacrificed wild-type C7BL/
6 animals following a 16-hour overnight fast. Consistent with our
in vitro observations, hepatic expression of Ago2 was observed
decreased in fasted animals compared to levels in the random-fed
cohort (Figure 1F). To further test whether this correlation was also
consistent in vivo in a mouse model of hyperglycemia, we measured
hepatic expression of Ago2 in leptin-deficient Lepob/ob animals and
observed higher levels compared to control littermates in the random-
fed state (Figure 1G).
3.2. Conditional deletion of Argonaute2 in liver reduces fasting
hepatic gluconeogenesis
To further test the role of Ago2 in hepatic glucose metabolism, we
then generated a conditional, liver-specific, Argonaute2 knockout
mouse model by crossing the Albumin-Cre mouse line with an Ago2
conditional allele (Alb-Cre, Ago2flox/flox) (Figure 2A,B). To determine
whether loss of hepatic Ago2 expression impacts systemic glucose
homeostasis, we measured blood glucose levels at random steady-
state and during an overnight 16-hour fast. In comparison to control
littermates, Albumin-Cre, Ago2flox/flox (Alb-Cre, Ago2flox/flox) mice
exhibited decreased blood glucose levels only after the prolonged
fast (Figure 2C). While no alterations were observed in body weight,
insulin sensitivity and glucose tolerance (Figure 2DeF), blood
glucose levels were significantly lower in Ago2-deficient mice after
pyruvate challenge compared to wild-type control littermates indi-
cating Ago2 contributes to hepatic glucose production (Figures 2G).
To further test the function of Ago2 in gluconeogenesis, we placed
Alb-Cre, Ago2flox/flox mice on a ketogenic diet for 30 days and
exhibited decreased blood glucose levels in comparison to wild-type
littermates (Figure 2H). Collectively, our results implicate an
essential role for Ago2 in hepatic glucose production and indicate
that Ago2/miRNA-mediated gene regulation facilitates adaptive
physiologic processes.
In line with our earlier observations, fasting expression of glucose-6-
phosphatase (G6pc), phosphoenolpyruvate carboxykinase (Pepck)
and pyruvate carboxylase (Pc1) in the liver of Alb-Cre, Ago2flox/flox mice
was decreased in comparison to levels in wild-type littermates
(Figure 2I). In addition, we could confirm that glucose-6 phosphatase
(G6Pase), glucokinase (Gck), and glycogen synthase2 (Gys2) were all
reduced in livers of Alb-Cre, Ago2flox/flox mice compared to wild-type
littermates by western blotting thereby further underlining the asso-
ciation between Ago2 and mediators of glucose metabolism
(Figure 2J). No significant change was observed in fasting plasma
insulin levels (Figure 2K); however, expression of the insulin receptor,
and the phosphorylated levels of Akt2 (at Ser473), and FoxO1 (at
Thr24) were decreased in Alb-Cre, Ago2flox/flox mice compared tocess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 17
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Figure 1: Argonaute2 in liver is modulated according to glucose metabolism. A, Western blotting analysis of Ago2 and glucokinase (Gck) in the isolated hepatocytes of 10-
week-old WT mice that were treated ex vivo with 2.5 and 25 mM glucose (n ¼ 3). B, Quantitative RT-PCR analysis of Ago2, Ago1, Gck, G6pase, Pyruvate carboxylase (Pc1),
and Phosphoenolpyruvate Caroxykinase (Pepck) in the isolated hepatocytes of 10-week-old WT mice after treatment of 2.5 and 25 mM of glucose (n ¼ 3 for both con-
centrations) for 48 h. C, D, Western blotting analysis of Ago2 in the isolated hepatocytes of 10-week-old WT mice after treatment with 0, 2.5, or 25 mM 2-deoxyglucose (2-DG)
for 16 h (n ¼ 3). E, Western blotting analysis of Ago2 in the isolated hepatocytes of 10-week-old WT mice after receiving 0 or 25 mM glucokinase activator (RO-28e1675) for
16 h (n ¼ 2). F, Western blotting analysis of Ago2 and Gck from the liver of 10-week-old WT mice fasted for 16 h (n ¼ 3). G, Western blotting analysis of Ago2 and Gck from
the liver of 10-week-old Lepob/ob mice and wild-type (WT) littermates (n ¼ 3). Results are presented as mean  SEM. *P < 0.05.
Original Articlelittermate controls indicating endogenous Ago2 impacts the insulin
signaling cascade within the hepatocyte (Figure 2L, M).
3.3. Loss of Ago2 abolishes miRNA-mediated targeting of AMPKa1
To elucidate the molecular basis for the role of Ago2 in hepatic glucose
control, we next sought to identify candidate target genes that are
bound by Ago2:miRNA complexes. We first hypothesized that AMPKa
may be subject to Ago2:miRNA-mediated gene regulation in the liver in
light of its established role as a key mediator of hepatic glucose
production and as a cellular stress sensor [21]. Indeed, the TargetScan
algorithm identifies a putative binding site for miR-148a (also known
asmiR-148a-3p), an abundant miRNA present in the liver, within the 3’
UTR of AMPKa1 (also known as PRKAA1 and in mouse as Prkaa1)
(Supplementary Figure 1 and Supplementary Table 2) [22]. To first
establish the direct interaction between Ago2, miR-148a, and the
AMPKa1 mRNA, we prepared liver lysates from wild-type C57BL/6
mice during random-fed and fasted states. Immunoprecipitation of
Ago2 recovered increased levels of both miR-148a and AMPKa1
mRNA from the lysates derived from random-fed mice compared to
those from fasted mice indicating the interaction between these
molecules is greater in the ad libitum state (Figure 3A). We further
examined other abundant liver miRNAs in the Ago2 pull-down assay,
including miR-122, miR-152 and miR-16, and measured increased
levels of these sequences indicating that in the random-fed state,
additional miRNAs will also bind to Ago2 (Figure 3A).
We next tested whether hepatic expression of AMPK was altered in
Alb-Cre, Ago2flox/flox mice to determine whether loss of Ago2
expression would disrupt potential miRNA-mediated regulation of
AMPKa1. Western blotting analysis using an antibody raised to detect
AMPKa revealed a marked increase in expression as well as its
phosphorylated form (at threonine 172 (Thr172) in liver lysates from
Alb-Cre, Ago2flox/flox mice in comparison to controls at age 10 weeks
(Figure 3B). This increase in AMPKa expression is consistent with
both disrupting miRNA-mediated gene regulation of a putative target
as well as the decrease in fasting glucose levels observed in these18 MOLECULAR METABOLISM 18 (2018) 15e24  2018 The Authors. Published by Elsevier GmbH. TAgo2-deficient mice. Moreover, we observed that the expression of
miR-148a was decreased in the livers of Alb-Cre, Ago2flox/flox mice
compared to littermate controls suggesting Ago2 may contribute to
the stability of this sequence in the hepatocyte (Figure 3C). To confirm
AMPKa1 as a direct target of miR-148a, we over-expressed this
miRNA in the presence of a luciferase reporter construct containing
the region of the AMPKa1 3‘-UTR that bears the putative binding site.
Transfection of a miR-148a mimic resulted in the suppression of
luciferase activity further suggesting this miRNA may directly target
the AMPKa1 gene (Figure 3D). Meanwhile, the transfection of mimics
for which there is no binding site in the UTR fragment including miR-
27b, miR-124, and miR-128 did not affect luciferase reporter activity
as expected and further supports the specificity of the interaction
between miR-148a and the AMPKa1 UTR. To further determine
whether AMPKa1 is directly targeted by miR-148a, we transfected
miRNA mimics into primary hepatocytes derived from C57BL/6 mice
and observed decreased protein and mRNA expression after
increasing intracellular concentrations of miR-148a in comparison to
the control pool of mimics (Figure 3E,F).
To address the physiologic relevance of the miR-148a targeting of
AMPKa1, we next followed up on our previous results by quantifying
hepatic AMPKa expression after fasting and during random-fed,
steady state in hyperglycemic Lepob/ob animals. Consistent with its
role in miRNA-mediated, gene silencing, we observed that decreased
expression of Ago2 in the livers of wild-type C57BL/6 mice after a 16-
hour overnight fasting was accompanied by increased expression of
AMPKa (Figure 3G). Conversely, increased hepatic expression of Ago2
in Lepob/ob animals in the random-fed state is accompanied by
decreased AMPKa expression (Figure 3H). Together these results
illustrating the inverse relationship between Ago2 and AMPKa ac-
cording to glycemic state provide further evidence for an important role
for miRNA:Ago2-mediated gene regulation in the maintenance of
systemic glucose homeostasis.
The effects on AMPKa expression in both the fasted and Lepob/ob
models also led to alterations in the phosphorylation of AMPKa (athis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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controls (n ¼ 14) from 4 to 12 weeks of age. E, Glucose measurements during an insulin tolerance test on 10-week old Alb-Cre, Ago2flox/flox mice (n ¼ 5) and littermate controls
(n ¼ 6). F, Glucose measurements during a glucose tolerance test on 11-week old Alb-Cre, Ago2flox/flox mice (n ¼ 7) and littermate controls (n ¼ 6). G, Glucose measurements
during a pyruvate tolerance test on 12-week old Alb-Cre, Ago2flox/flox mice (n ¼ 5) and littermate controls (n ¼ 6). H, Glucose measurements and body weight in the Alb-Cre,
Ago2flox/flox mice (n ¼ 8) and littermate controls (n ¼ 4) on normal chow (Chow) or ketogenic diet (Keto, n ¼ 8) for 30 days. I, qRT-PCR analysis of G6Pase, Pepck and Pyruvate
carboxylase (Pc1) from liver of 8-week-old Alb-Cre, Ago2flox/flox mice (n ¼ 5) and littermate controls after overnight fasting (n ¼ 6). J, Western blotting analysis of glucose-6
phosphatase (G6Pase), glucokinase (Gck) and glycogen synthase (Gly synth) from liver of 8-week-old Alb-Cre, Ago2flox/flox mice and littermate controls after overnight fasting
(n ¼ 3). K, Plasma insulin measurements in 12-week old Alb-Cre, Ago2flox/flox mice (n ¼ 7) and littermate controls after overnight fasting (n ¼ 6). L, Western blotting analysis of
Ago2 and Ago1 from liver of 8-week-old Alb-Cre, Ago2flox/flox mice and littermate controls during random-fed and overnight fasted states (16 h) (n ¼ 2). M, Western blotting analysis
of insulin receptor (InsR), phosphorylated Akt2 at Ser473 (p-Akt2), Akt2, phosphorylated FoxO1 at Thr24 (p-FoxO1) and FoxO1 from liver of 8-week-old Alb-Cre, Ago2flox/flox mice and
littermate controls during random-fed and overnight fasted states (16 h) (n ¼ 2). Results are presented as mean  SEM. *P < 0.05, **P < 0.01 and ***P < 0.001.Thr172) indicating concomitant changes in activity may also impact
other mechanisms including lipid metabolism in addition to hepatic
gluconeogenesis (Figure 3G,H). Acetyl-CoA carboxylase (ACC) is a
prominent target of AMPKa and a key regulator of hepatic fatty acid
metabolism and western blotting analysis of livers from Alb-Cre,
Ago2flox/flox and littermate control mice revealed increasedMOLECULAR METABOLISM 18 (2018) 15e24  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comphosphorylation of ACC at serine 79 (Ser79) in the Ago2-deficient
animals (Figure 3I). This was consistent with increased expression
of total ACC expression, meanwhile no significant change was
observed in fatty acid synthase (FAS) (Figure 3I). While Alb-Cre,
Ago2flox/flox mice do not exhibit any alteration in total liver weight
(Figure 3H), a mild increase in total hepatic triglyceride content wascess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 19
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Original Articlemeasured in the livers of Ago2-deficient mice (Figure 3K). These re-
sults begin to indicate Ago2-mediated gene regulation can impact the
pathways regulating both glucose and lipid metabolism.
3.4. Loss of Ago2 improves glucose homeostasis in models of
hyperglycemia, obesity and insulin resistance
To further test the in vivo relevance of Ago2 in the regulation of hepatic
glucose production, we next crossed Alb-Cre, Ago2flox/flox mice onto
the Lepob/ob background (referred to as ob/Ago2Alb mice) (Figure 4A).
Interestingly, ob/Ago2Alb mice exhibited lower body weight compared
to their Lepob/ob littermate controls due in large part to reduced fat20 MOLECULAR METABOLISM 18 (2018) 15e24  2018 The Authors. Published by Elsevier GmbH. Tmass (Figure 4B,C). Whereas no change in body weight was observed
in Alb-Cre, Ago2flox/flox mice, loss of Ago2 in the context of physiologic
stress elicited significant differences in metabolic parameters relevant
to energy homeostasis. We next examined circulating glucose and
insulin levels to see whether Ago2 would affect other signature fea-
tures of the Lepob/ob phenotype. Blood glucose and plasma insulin
measurements were decreased in ob/Ago2Alb mice in comparison to
Lepob/ob littermates at random-fed and fasting states further sup-
porting our observations on the role of Ago2 in regulating hepatic
gluconeogenesis and insulin sensitivity (Figure 4DeF). In addition,
blood glucose levels were also lower in the Ago2-deficient animalshis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original Articleduring glucose and insulin tolerance tests indicating that specific
targeting of Ago2 in the hepatocyte has extensive impact on systemic
energy metabolism (Figure 4G,H). As we observed previously in Alb-
Cre, Ago2flox/flox mice, hepatic G6Pase and Gck expression as well as
phospho-Akt2 and phospho-FoxO1 were all similarly reduced in the
livers of ob/Ago2Alb mice when compared to expression in Lepob/ob
controls (Figure 4IeK). Furthermore, we also confirmed on the Lepob/ob
background that loss of Ago2 incurs a reduction of miR-148a
expression (Figure 4L). Likewise, the hepatic expression of AMPKa
was increased in the livers of these animals, consistent with abolishing
its regulation by the miRNA pathway (Figure 4M). Expression of both
ACC and FAS were also observed increased in the livers of ob/Ago2Alb
mice when compared to expression in littermate Lepob/ob controls
(Figure 4N). While the increased expression of lipogenic enzymes
would be expected to promote hepatic lipid accumulation as in Alb-Cre,
Ago2flox/flox mice, we observed no significant change in total liver tri-
glyceride content in ob/Ago2Alb mice in comparison to Lepob/ob litter-
mates (Figure 4O). Furthermore, analysis of genes regulating fatty acid
metabolism by quantitative RT-PCR only revealed a subtle increase in
lipoprotein lipase (Lpl) (Figure 4P). While increased expression of he-
patic Lpl would be consistent with an increase in circulating free fatty
acids, we observed no change in plasma FFA levels in ob/Ago2Alb mice
suggesting their uptake may also be elevated by peripheral tissues
(Supplementary Table 1).
4. DISCUSSION
Numerous mechanisms at both the systemic and cellular level are
present to aid in the adaptation to nutrient availability; however, the
ongoing characterization of these pathways continues to expand the
identification of molecules contributing to the regulation of energy
metabolism [23]. By now, the microRNA pathway has been linked to
virtually all cellular processes, yet a great deal still remains to be
clarified regarding the functional role of these non-coding RNAs [24].
Here we report on the conditional loss of function mouse model of
Ago2 in the hepatocyte which illustrates a role for this RNA-binding
protein and its associated miRNAs in maintaining fasting glucose
levels. We identify AMPKa1, a mediator of hepatic glucose and lipid
metabolism, as an intracellular target of miR-148a thereby directly
linking non-coding RNAs to a key sensor of cellular stress in the liver.
As all living organisms depend on glucose for energy, mechanisms
have evolved to manage cellular metabolism as demands fluctuate.
Our observations here in the hepatocyte continue to allude to the
broader role for the miRNA pathway as a central regulator of adaptive
physiology that responds to changes in nutrient availability. One pri-
mary aspect of cell biology that remains unclear is how individual cells
manage their intracellular metabolism to simultaneously maintain all of
the ongoing functions performed by the cell. In the case of the
pancreatic b-cell, we previously showed that loss of Ago2 and miR-
375 in this cell type abolished compensatory proliferation in response
to an increase in the demand for insulin during insulin resistance and
hyperglycemia [12,25]. It is clear in this cellular context that, as the
demand for insulin increases, the miRNA pathway acts to manage the
balance between the energy requirements mandated for proliferation
versus those that are necessary for exocytosis.
Here in the case of the hepatocyte, the reduction in glucose output
during fasting again suggests that Ago2 and the microRNA pathway are
central to maintaining a balance in cellular energy expenditure between
multiple processes relying on the same energy pool. Our results
showing reduced body weight and fat mass in the ob/Ago2Alb model in
comparison to Lepob/ob littermates clearly indicates deletion of hepatic22 MOLECULAR METABOLISM 18 (2018) 15e24  2018 The Authors. Published by Elsevier GmbH. TAgo2 impacts lipid metabolism in both the adipose and liver tissues.
The reduction in adipose mass and in circulating triglycerides observed
in ob/Ago2Alb animals is likely to be prompted by the overall improve-
ment in glycemia, circulating insulin, and insulin sensitivity directly
resulting from the loss of hepatic Ago2 and the concomitant increase in
AMPKa. Importantly, transient activation of AMPKa in liver was similarly
shown to reduce fasting blood glucose levels and adipose mass, as well
as increase liver triglyceride content suggesting the de-repression of
AMPKa is a robust component of the Ago2 knockout phenotype [26].
As hepatic AMPK expression is promoted during fasting, it is reason-
able to speculate that Ago2 and its associated miRNAs are recruited to
bind the 3‘-UTR of targeted genes such as AMPKa1 to halt translation
as its functional demand fades such as in the post-prandial state; and
when demand for expression has ceased for a prolonged period, the
cell initiates the degradation of that mRNA perhaps as an ‘energy
saving’ mechanism via the network of RNA-binding proteins that
facilitate mRNA decay. In the context of human metabolism, cells such
as beta cells or hepatocytes require mechanisms to handle sudden
bouts of increased extracellular glucose and glucose influx during the
day. Since these feeding events may be separated by a few hours or
less, it is also plausible for cells to maintain and protect the integrity of
essential transcripts perhaps by miRNA:Ago complexes to efficiently
manage gene expression according to fluctuations in metabolic de-
mand. At the cellular level, from an energy expenditure standpoint, this
would be logical as opposed to constantly cycling between transcribing
and decaying mRNAs in between feeding events.
While the precise mechanism remains unknown, this link between
Ago2 and AMPKa may constitute a key switch between glucose and
fatty acid metabolism. The decrease in plasma triglycerides may result
from the increase in LPL expression that we measured in the livers of
Ago2-deficient mice. While LPL expression is generally low in the liver,
it has been shown to be up-regulated in conditions of low carbohydrate
availability and increased expression of hepatic AMPK [26,27]. While
Ago2 undoubtedly mediates the targeting of dozens of genes in the
hepatocyte, it has not been established whether the up-regulation of
genes such as LPL and ACC in our loss of function models is due to de-
repression of miRNA targeting and should be subject to further
investigation. Nonetheless, these results continue to delineate the
complex network of prominent protein and non-coding RNA factors
that maintain essential physiologic processes.
In light of these findings, future studies will eventually establish the full
extent to which miRNA:Ago2-mediated gene regulation is in control of
glucose and lipid homeostasis in the hepatocyte. As miR-122 has long
been known to be the most abundant miRNA in the liver (and therefore
should occupy a large percent of Ago2 present in the hepatocyte), it
should also be noted that there are significant areas of phenotypic
overlap between our results presented here and the published studies
on the miR-122-knockout mouse [5,7]. As shown in both loss of miR-
122 studies, Alb-Cre, Ago2flox/flox mice also exhibited reduced triglyc-
eride levels in circulation; however we did not observe any alterations in
circulating cholesterol as previously reported [5,7,28]. Additionally, we
did not observe the development of spontaneous liver tumors in Alb-
Cre, Ago2flox/flox mice through the age of 14 months in contrast to both
papers on the miR-122 knockout animals. While miR-122 is likely to
interact with a large part of the Ago2 pool, the most plausible expla-
nation for these differences are the compensatory actions by either
Ago1 or the collective loss of function of other miRNAs in our Alb-Cre,
Ago2flox/flox model which offset or delay these phenotypic outcomes.
In addition to identifying additional Ago2-associated miRNAs and tar-
gets, several aspects of hepatic Ago2 function that should be further
clarified include the identification of interacting proteins which affecthis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
its function according to metabolic state. Previous studies have also
shown that mitogenic signals may promote the recruitment of Ago2 to
complex with other proteins suggesting additional proteins facilitate
miRNA targeting [29]. Furthermore, recent studies have identified
dozens of RNA-binding proteins that bind miRNAs and influence their
expression thereby potentially increasing the complexity of studying
miRNA-mediated gene targeting [30,31]. Lastly, it has also been
shown that several phosphorylation sites are present on Ago2 and
these sites have been shown to impact target gene suppression by
miRNA [32] [33]. These recent studies have uncovered numerous in-
tricacies of miRNA:Argonaute function and elucidating these dynamics
within metabolic processes will continue to provide new insight into the
pathways driving systemic energy homeostasis.
5. CONCLUSIONS
The ongoing examination of the miRNA pathway continues to clarify its
functional association with virtually all cellular processes. In this study
using genetic mouse models, we demonstrate that deletion of Ago2
results in lower systemic glucose levels during fasting and during the
random-fed state in hyperglycemic Lepob/ob mice further supporting
this pathway as a mediator of adaptive cell physiology. Future studies
aimed at miRNA:Ago-mediated gene regulation will continue the
mapping of distinct networks that regulate energy metabolism and will
facilitate the identification of mechanisms that may be pharmacolog-
ically targeted to reverse the onset of diabetes and obesity.
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